- In February 2025, Becton, Dickinson and Company (BD) introduced an advanced pen needle designed for enhanced patient safety and usability, featuring a tactile grip and audible click feedback. These improvements aim to help patients, particularly those managing diabetes at home, perform injections with greater confidence and precision.
- In September 2024, Novo Nordisk received CE Mark approval for an eco-friendly pen needle compatible with smart insulin pens. This innovation not only supports digital health integration but also addresses environmental concerns, which are increasingly influencing medical device development.
- In May 2024, Ypsomed introduced a short safety needle with extra-thin wall technology that enhances medication flow rate and reduces penetration force. This innovation enhances patient comfort and efficiency during insulin administration, supporting the trend toward less invasive, more user-friendly solutions. It also responds to growing demand for safety-engineered devices in both clinical and home settings
- In March 2024, MTD Group acquired Ypsomed’s pen needle and blood glucose monitoring businesses, significantly expanding its market presence and product portfolio in diabetes care
- In July 2024, Embecta Corp. announced it was exploring a potential sale of the company due to reduced profitability and valuation drop, indicating consolidation trends and shifting business strategies in the insulin delivery market
